Efficacy of humanized carbapenem and ceftazidime regimens against enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1678-1683

  Wiskirchen, Dora E ^a   Nordmann, Patrice ^b,c   Crandon, Jared L ^d   Nicolau, David P ^d  

^a UNIVERSITY OF SAINT JOSEPH   (United States)

^b Associated French National Reference Center for Antibiotic Resistance: Carbapenemase producing Enterobacteriaceae   (France)

^c University of Fribourg   (Switzerland)

^d HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; CEFTAZIDIME; CYCLOPHOSPHAMIDE; DORIPENEM; ERTAPENEM; LEVOFLOXACIN; OXA 48 CARBAPENEMASE; PENICILLINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; ENTEROBACTERIACEAE INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; CEFTAZIDIME; DISEASE MODELS, ANIMAL; HUMANS; KLEBSIELLA PNEUMONIAE; LEVOFLOXACIN; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS;

EID: 84896879064     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01947-13     Document Type: Article

References (24)

1. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase- producing Enterobacteriaceae. Emerg. Infect. Dis. 17:1791-1798. http://dx.doi.org/10.3201/eid1710.110655.
2. Poirel L, Potron A, Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J. Antimicrob. Chemother. 67:1597-1606. http://dx.doi.org/10. 1093/jac/dks121.
3. Poirel L, Heritier C, Tolun V, Nordmann P. 2004. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48:15-22. http://dx.doi.org/10.1128/AAC.48.1.15- 22.2004. (Pubitemid 38040171)
4. Docquier JD, Calderone V, De Luca F, Benvenuti M, Giuliani F, Belluci Tafi A, Nordmann P, Botta M, Rossolini GM, Mangani S. 2009. Crystal structure of the OXA-48 β-lactamase reveals mechanistic diversity among class D carbapanemases. Chem. Biol. 16:540-547. http://dx.doi.org/10.1016/j.chembiol. 2009.04.010.
5. Mimoz O, Gregoire N, Poirel L, Marliat M, Couet W, Nordmann P. 2012. Broad-spectrum β-lactam antibiotic for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48. Antimicrob. Agents Chemother. 56:2759-2760. http://dx.doi.org/10.1128/AAC.06069- 11.
6. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. 2013. Efficacy of humanized carbapenem exposures against New Delhi metallo-betalactamase (NDM-1) producing Enterobacteriaceae in a murine infection model. Antimicrob. Agents Chemother. 57:3936-3940. http://dx.doi.org/10.1128/AAC.00708-13.
7. Wiskirchen DE, Crandon JL, Nicolau DP. 2013. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 41:582-585. http://dx.doi.org/10.1016/j. ijantimicag.2013.02.015.
8. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI publication M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Lascols C, Peirano G, Hackel M, Laupland KB, Pitout JDD. 2013. Surveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce carbapenemases: first report of OXA-48-like enzymes in North America. Antimicrob. Agents Chemother. 57:130-136. http://dx.doi.org/10.1128/AAC.01686- 12.
10. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379. (Pubitemid 28420381)
11. Deryke CA, Banevicius MA, Fan HW, Nicolau DP. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum-β- lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob. Agents Chemother. 51:1481-1486. http://dx.doi.org/10.1128/AAC.00752-06. (Pubitemid 46586832)
12. Crandon JL, Bulik CC, Nicolau DP. 2009. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4352-4356. http://dx.doi.org/10. 1128/AAC.00282-09.
13. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:6137-6146. http://dx.doi.org/10. 1128/AAC.00851-12.
14. Onyeji CO, Bui KQ, Owens RC, Nicolau SP, Quintiliani R, Nightingale CH. 1999. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int. J. Antimicrob. Agents 12:107-114. http://dx.doi.org/10.1016/S0924-8579(98)00087-9. (Pubitemid 29276912)
15. Keel RA, Crandon JL, Nicolau DP. 2011. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:4028-4032. http://dx.doi.org/10.1128/AAC.00372-11.
16. Bush K. 2013. The ABCD's of - lactamase nomenclature. J. Infect. Chemother. 19:549-559. http://dx.doi.org/10.1007/s10156-013-0640-7.
17. Goren MG, Chmelnitsky I, Carmeli Y, Navon-Venezia S. 2011. Plasmid-encoded OXA-48 carbapenemase in Escherichia coli from Isreal. J. Antimicrob. Chemother. 66:672-673. http://dx.doi.org/10.1093/jac/dkq467.
18. Turnidge JD. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22. http://dx.doi.org/10.1086/514622.
19. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081. http://dx.doi.org/10.1128/AAC.37.5. 1073. (Pubitemid 23141323)
20. Levast M, Poirel L, Carrer A, Deiber M, Decroisette E, Mallaval FO, Lecomte C, Nordmann P. 2011. Transfer of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae from Turkey to France. J. Antimicrob. Chemother. 66:944-945. http://dx.doi.org/10.1093/jac/dkq504.
21. Potron A, Poirel L, Rondinaud E, Nordmann P. 2013. Intercontinental spread of OXA-48 beta-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. Euro Surveill. 18(31):pii=20549. http://www. eurosurveillance.org/ViewArticle.aspx?ArticleId=20549.
22. Carrer A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P. 2008. Spread of OXA-48 positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob. Agents Chemother. 52:2950-2954. http://dx.doi.org/10.1128/AAC.01672-07.
23. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. 2011. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob. Agents Chemother. 585:2420-2423. http://dx.doi.org/10.1128/AAC. 01452-10.
24. Mathers AJ, Hazen K, Carroll J, Yeh AJ, Cox HL, Bonomo RA, Sifri CD. 2013. First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the "menace" arrives in the new world. J. Clin. Microbiol. 51:680-683. http://dx.doi.org/10.1128/JCM.02580-12.